RARE Past Earnings image   This RARE past earnings page last updated 5/6/2024
RARE Past Earnings
PeriodPast Earnings DateGAAP
Q1 20245/2/2024-2.030
Q4 20232/15/2024-1.520
Q3 202311/2/2023-2.230
Q2 20238/3/2023-2.250
Q1 20235/4/2023-2.330
Q4 20222/16/2023-2.160
Q3 202211/2/2022-2.430
Q2 20227/28/2022-2.260
Q1 20225/5/2022-2.190
Q4 20212/10/2022-1.790
Q3 202111/2/2021-1.080
Q2 20218/2/2021-1.810
Q1 20215/4/2021-2.030
Q4 20202/11/2021-0.370
Q3 202010/27/2020-1.130
Q2 20207/30/2020-1.120
Q1 20205/6/2020-2.050
Q4 20192/13/2020-1.620
Q3 201911/5/2019-1.960
Q2 20198/1/2019-1.720
Q1 20195/6/2019-1.820
Q4 20182/19/2019-1.73
Q3 201811/5/2018-1.74
Q2 20188/2/2018-1.87
Q1 20185/7/2018-2.03
Q4 20172/20/2018-1.52
Q3 201711/2/2017-1.87
Q2 20177/27/2017-1.72
Q1 20175/4/2017-1.63
Q4 20162/16/2017-1.75
Q3 201611/7/2016-1.64
Q2 20168/8/2016-1.46
Q1 20165/9/2016-1.35
Q4 20152/25/2016-1.42
Q3 201511/9/2015-1.03
Q2 20158/13/2015-0.83
Q1 20155/11/2015-0.63
Q4 20143/25/2015-0.52
Q3 201411/10/2014-0.5
Q2 20148/11/2014-0.45
Q1 20145/12/2014-0.85
RARE Past Revenue
PeriodPast Earnings DateGAAP
Q1 20245/2/20240.11B
Q4 20232/15/20240.13B
Q3 202311/2/20230.10B
Q2 20238/3/20230.11B
Q1 20235/4/20230.10B
Q4 20222/16/20230.10B
Q3 202211/2/20220.09B
Q2 20227/28/20220.09B
Q1 20225/5/20220.08B
Q4 20212/10/20220.08B
Q3 202111/2/20210.08B
Q2 20218/2/20210.09B
Q1 20215/4/20210.10B
Q4 20202/11/20210.09B
Q3 202010/27/20200.08B
Q2 20207/30/20200.06B
Q1 20205/6/20200.04B
Q4 20192/13/20200.04B
Q3 201911/5/20190.03B
Q2 20198/1/20190.02B
Q1 20195/6/20190.02B
Q4 20182/19/201916.26M
Q3 201811/5/201811.76M
Q2 20188/2/201812.79M
Q1 20185/7/201810.68M
Q4 20172/20/20182.41M
Q3 201711/2/2017198000
Q2 20177/27/2017NA
Q1 20175/4/2017NA
Q4 20162/16/20175000
Q3 201611/7/2016111000
Q2 20168/8/201617000
Q1 20165/9/2016NA
Q4 20152/25/2016NA
Q3 201511/9/2015NA
Q2 20158/13/2015NA
Q1 20155/11/2015NA
Q4 20143/25/2015NA
Q3 201411/10/2014NA
Q2 20148/11/2014NA
Q1 20145/12/2014NA
Quotes delayed 20 minutes

Email EnvelopeFree RARE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Ultragenyx Pharmaceutical (RARE) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

RBOT Past Earnings
RCEL Past Earnings
RCKT Past Earnings
RCUS Past Earnings
RDNT Past Earnings
REGN Past Earnings
RENB Past Earnings
REPH Past Earnings
REPL Past Earnings
RETA Past Earnings

RARE Past Earnings Q&A

What was the best and worst RARE past earnings results?
For Ultragenyx Pharmaceutical, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest RARE past earnings result in our data set was -0.370/share posted in Q4 2020, while the lowest was in Q3 2022 when RARE posted -2.430/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q4 2023 when RARE reported 0.13B in revenue, while the quarter with the lowest revenue in our data set was Q2 2017 at NA of revenue.

  Suggested answer: There are 41 RARE past earnings results in our data set.

On this page we presented the RARE past earnings date information for Ultragenyx Pharmaceutical. Reviewing that RARE Past Earnings for the company, we see that the highest past earnings result in our data set was in Q4 2020, when RARE posted gaap of -0.370/share. Meanwhile the lowest RARE past earnings result was in Q3 2022, when RARE posted gaap of -2.430/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q4 2023 when RARE reported 0.13B in revenue, while the smallest revenue quarter was Q2 2017 when RARE reported NA in revenue.

Any self directed investor doing their due diligence on RARE or any other given stock can benefit from researching all of the Ultragenyx Pharmaceutical past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Ultragenyx Pharmaceutical past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for RARE. Thanks for visiting, and the next time you need to research RARE past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: QDEL Videos, FPO Price Target, FLJP Options Chain.


RARE Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2024, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
Wait! Don't leave yet.
Want to receive our latest research absolutely free?

Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.